Ultragenyx Pharmaceutical (RARE) Competitors

Genmab A/S (NASDAQ:GMAB) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, community ranking, institutional ownership, dividends and earnings.

Is GMAB or RARE more profitable?

Genmab A/S has a net margin of 36.30% compared to Ultragenyx Pharmaceutical's net margin of -101.60%. Genmab A/S's return on equity of 16.78% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	36.30%	16.78%	13.79%
Ultragenyx Pharmaceutical	-101.60%	-193.80%	-38.15%

Do insiders and institutionals hold more shares of GMAB or RARE?

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 5.8% of Ultragenyx Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Which has more volatility and risk, GMAB or RARE?

Genmab A/S has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500.

Which has higher earnings & valuation, GMAB or RARE?

Genmab A/S has higher revenue and earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$21.53B	0.60	$1.14B	$1.74	11.21
Ultragenyx Pharmaceutical	$560.23M	5.92	-$569.18M	-$6.34	-5.57

Does the media favor GMAB or RARE?

In the previous week, Genmab A/S had 13 more articles in the media than Ultragenyx Pharmaceutical. MarketBeat recorded 23 mentions for Genmab A/S and 10 mentions for Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical's average media sentiment score of 1.29 beat Genmab A/S's score of 0.72 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	7 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Ultragenyx Pharmaceutical	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Does the MarketBeat Community prefer GMAB or RARE?

Ultragenyx Pharmaceutical received 671 more outperform votes than Genmab A/S when rated by MarketBeat users. Likewise, 77.52% of users gave Ultragenyx Pharmaceutical an outperform vote while only 63.02% of users gave Genmab A/S an outperform vote.

Company	Underperform	Outperform
Genmab A/S	Outperform Votes 167 63.02%	Underperform Votes 98 36.98%
Ultragenyx Pharmaceutical	Outperform Votes 838 77.52%	Underperform Votes 243 22.48%

Do analysts prefer GMAB or RARE?

Genmab A/S presently has a consensus price target of $39.17, indicating a potential upside of 100.75%. Ultragenyx Pharmaceutical has a consensus price target of $92.79, indicating a potential upside of 162.55%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Ultragenyx Pharmaceutical	0 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.93

Summary

Genmab A/S beats Ultragenyx Pharmaceutical on 10 of the 19 factors compared between the two stocks.